Anna Leitgeb

Title: Anna Leitgeb: Innovator in Chemically Modified Heparins

Introduction

Anna Leitgeb is a prominent inventor based in Saltsjöbaden, Sweden. She has made significant contributions to the field of medical science, particularly in the development of chemically modified heparins. With a total of 2 patents, her work focuses on innovative treatments for serious health conditions.

Latest Patents

Leitgeb's latest patents include groundbreaking inventions that address critical medical needs. One of her notable patents is for low anticoagulant heparins, which relates to a chemically modified heparin with an antifactor II activity of less than 10 IU/mg and an antifactor Xa activity of less than 10 IU/mg. This invention also specifies an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Additionally, she has developed a method for preparing this heparin and its medical use, including treatment for malaria. Another significant patent involves the use of chemically modified heparin derivatives in the treatment of sickle cell disease, again with specific activity and molecular weight parameters.

Career Highlights

Throughout her career, Anna Leitgeb has worked with notable companies such as Dilaforette AB and Modus Therapeutics AB. Her expertise in the field has allowed her to contribute to advancements in medical treatments and therapies.

Collaborations

Leitgeb has collaborated with esteemed colleagues, including Hans-Peter Ekre and Mats Wahlgren. These partnerships have further enhanced her research and development efforts in the medical field.

Conclusion

Anna Leitgeb's innovative work in chemically modified heparins showcases her dedication to improving medical treatments. Her patents reflect her commitment to addressing significant health challenges, making her a valuable contributor to the field of medical science.